Professional Documents
Culture Documents
Menorrhagia: Kirsten Duckitt and Sally Collins
Menorrhagia: Kirsten Duckitt and Sally Collins
..................................................
Menorrhagia
Search date October 2007
Kirsten Duckitt and Sally Collins
ABSTRACT
INTRODUCTION: Menorrhagia limits normal activities, and causes anaemia in two thirds of women with objective menorrhagia (loss of
80 mL blood per cycle). Prostaglandin disorders may be associated with idiopathic menorrhagia, and with heavy bleeding due to fibroids,
adenomyosis, or use of intrauterine devices (IUDs). Fibroids have been found in 10% of women with menorrhagia overall, and in 40% of
women with severe menorrhagia; but half of women having a hysterectomy for menorrhagia are found to have a normal uterus. METHODS
AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of medical
treatments for menorrhagia? What are the effects of surgical treatments for menorrhagia? What are the effects of endometrial thinning before
endometrial destruction in treating menorrhagia? We searched: Medline, Embase, The Cochrane Library, and other important databases
up to October 2007 (BMJ Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of
this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines
and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 39 systematic reviews, RCTs, or observational studies that
met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this system-
atic review we present information relating to the effectiveness and safety of the following medical interventions: combined pill, danazol,
etamsylate, gonadorelin analogues, intrauterine progesterone, non-steroidal inflammatory drugs (NSAIDs), progestogens, and the following
surgical interventions: dilatation and curretage, endometrial destruction, and hysterectomy.
QUESTIONS
What are the effects of medical treatments for menorrhagia?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
What are the effects of surgical treatments for menorrhagia?. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
What are the effects of endometrial thinning before endometrial destruction in treating menorrhagia?. . . . . . 17
INTERVENTIONS
MEDICAL TREATMENTS tion; also reduces need for further surgery compared
with endometrial destruction) . . . . . . . . . . . . . . . . . 12
Beneficial
NSAIDs . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
Likely to be beneficial
Tranexamic acid . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
Endometrial destruction (reduces menstrual blood loss
compared with medical treatment) . . . . . . . . . . . . . 14
Trade off between benefits and harms
Danazol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Unknown effectiveness
Dilatation and curettage . . . . . . . . . . . . . . . . . . . . . 12
Unknown effectiveness
Contraceptives (combined oral) . . . . . . . . . . . . . . . . 8 PREOP ENDOMETRIAL THINNING
Etamsylate . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 6 Beneficial
Gonadorelin analogues . . . . . . . . . . . . . . . . . . . . . 12 Gonadorelin analogues . . . . . . . . . . . . . . . . . . . . . 17
Intrauterine progestogens . . . . . . . . . . . . . . . . . . . . 10
Progestogens (oral) for longer cycle . . . . . . . . . . . . 10 Unknown effectiveness
Progestogens (oral) in luteal phase only . . . . . . . . . 8 Danazol . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Progestogens (oral) . . . . . . . . . . . . . . . . . . . . . . . . 18
SURGERY
Beneficial Covered elsewhere in Clinical Evidence
Hysterectomy (reduces menstrual blood loss compared Fibroids (uterine myomatosis, leiomyomas)
with intrauterine progestogens or endometrial destruc-
Key points
• Menorrhagia limits normal activities, and causes anaemia in two thirds of women with objective menorrhagia (blood
loss of more than 80 mL blood per cycle).
Prostaglandin disorders may be associated with idiopathic menorrhagia, and with heavy bleeding caused by fibroids,
adenomyosis, or use of IUDs.
Fibroids have been found in 10% of women with menorrhagia overall, and in 40% of women with severe menor-
rhagia; but half of women having a hysterectomy for menorrhagia are found to have a normal uterus.
• NSAIDs, tranexamic acid, and danazol all reduce blood loss compared with placebo.
© BMJ Publishing Group Ltd 2008. All rights reserved. ..................... 1 ..................... Clinical Evidence 2008;09:805
Women's health
Menorrhagia
Tranexamic acid and danazol may be more effective than NSAIDs, etamsylate, and oral progestogens at reducing
blood loss, but any benefits of danazol must be weighed against the high risk of adverse effects.
NSAIDs reduce dysmenorrhoea, and may be as effective at reducing menstrual blood loss as oral progestogens
given in the luteal phase, but we don't know how they compare with etamsylate, combined oral contraceptives,
intrauterine progestogens, or gonadorelin analogues.
We don't know whether combined oral contraceptives, levonorgestrel-releasing intrauterine devices, or gonadorelin
analogues are effective at reducing menorrhagia, as few studies were found.
• Hysterectomy reduces blood loss, and reduces the need for further surgery compared with medical treatments or
endometrial destruction, but can lead to complications in up to a third of women.
Endometrial destruction is more effective at reducing menorrhagia compared with medical treatment, but compli-
cations can include infection, haemorrhage, and uterine perforation.
We don't know whether any one type of endometrial destruction is superior, or whether dilatation and curettage
has any effect on menstrual blood loss.
• Preoperative gonadorelin analogues reduce long-term postoperative moderate or heavy blood loss, and increase
amenorrhoea compared with placebo, but we don't know whether oral progestogens or danazol are also beneficial
when used preoperatively.
DEFINITION Menorrhagia is defined as heavy but regular menstrual bleeding. Idiopathic ovulatory menorrha-
gia is regular heavy bleeding in the absence of recognisable pelvic pathology or a general bleeding
disorder. Objective menorrhagia is taken to be a total menstrual blood loss of 80 mL or more in
[1]
each menstruation. Subjectively, menorrhagia may be defined as a complaint of regular excessive
menstrual blood loss occurring over several consecutive cycles in a woman of reproductive age.
INCIDENCE/ In the UK, 5% of women aged 30–49 years consult their general practitioners each year with
[2]
PREVALENCE menorrhagia. In New Zealand, 2–4% of primary-care consultations by premenopausal women
[3]
are for menstrual problems.
PROGNOSIS Menorrhagia limits normal activities and causes iron-deficiency anaemia in two thirds of women
[1] [6] [7]
proven to have objective menorrhagia. One in five women in the UK and one in three in
the USA have a hysterectomy before the age of 60 years; menorrhagia is the main presenting
[8] [9] [10]
problem in at least half of these women. About half of women who have a hysterectomy
[11]
for menorrhagia are found to have an anatomically normal uterus.
AIMS OF To reduce menstrual bleeding; improve quality of life; and prevent or correct iron-deficiency anaemia,
INTERVENTION with minimum adverse effects. Women may regard amenorrhea as a benefit or a harm of treatment,
depending on their perspective.
OUTCOMES Menstrual blood flow (assessed objectively [mL/cycle] or subjectively); haemoglobin concentration;
quality of life; patient satisfaction; incidence of adverse drug effects; and incidence of postoperative
complications. Whether a particular percentage reduction in menstrual blood loss is considered
clinically important will depend on pretreatment menstrual loss and on individual women's perceptions
of acceptable menstrual loss.
METHODS BMJ Clinical Evidence search and appraisal October 2007. The following databases were used to
identify studies for this review: Medline 1966 to October 2007, Embase 1980 to October 2007, and
The Cochrane Database of Systematic Reviews 2007, Issue 3. Additional searches were carried
out using these websites: NHS Centre for Reviews and Dissemination (CRD) — for Database of
Abstracts of Reviews of Effects (DARE) and Health Technology Assessment (HTA), Turning Re-
search into Practice (TRIP), and NICE clinical guidelines. Abstracts of the studies retrieved were
assessed independently by two information specialists using predetermined criteria to identify rel-
evant studies. Study design criteria for evaluation in this review were: published systematic reviews
and RCTs in any language, containing more than 20 individuals of whom more than 80% were
followed up. There was no minimum length of follow-up required to include studies. We excluded
all studies described as “open”, “open label”, or not blinded, unless blinding was impossible. In
addition, we use a regular surveillance protocol to capture harms alerts from organisations such
as the FDA and the UK Medicines and Healthcare products Regulatory Agency (MHRA), which
OPTION NSAIDS. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Comparing different NSAIDs Different NSAIDs may be equally effective at reducing mean menstrual blood loss,
based on a comparison between mefenamic acid and naproxen (low-quality evidence).
Compared with tranexamic acid NSAIDs may be less effective at reducing mean blood loss (very low-quality evidence).
Compared with etamsylate NSAIDs may be more effective at reducing mean blood loss (very low-quality evidence).
Compared with danazol NSAIDs are less effective at reducing mean blood loss (moderate-quality evidence).
Compared with combined oral contraceptives NSAIDs and oral contraceptives may be equally effective at reducing
mean blood loss (moderate-quality evidence).
Compared with oral progestogens (luteal phase) NSAIDs and oral progestogens given in the luteal phase are
equally effective at reducing mean blood loss (moderate-quality evidence).
Compared with progestogen-releasing IUD We don't know how effective NSAIDs are at reducing mean blood loss
compared with progestogen-releasing IUD (very low-quality evidence).
Adverse effects
NSAIDs have fewer adverse effects than danazol.
Note
We found no clinically important results about the effects of NSAIDs compared with gonadorelin analogues.
Harms: The reviews found that commonly reported adverse effects included headaches, and gastrointestinal
[3] [12]
disturbances such as indigestion, nausea, vomiting, and diarrhoea. These occurred in at
least 50% of women taking NSAIDs in the RCTs that reported data on adverse effects, but similar
levels of adverse effects were found in placebo cycles (see review on NSAIDs).
Comment: The comparisons of NSAIDs versus other drugs may have lacked power to exclude clinically im-
[12]
portant differences between treatments. Both reviews comparing NSAIDs versus danazol found
[13]
that NSAIDs were less effective than danazol in reducing blood loss, but the second review
did not perform a meta-analysis for this comparison.
Clinical guide:
NSAIDs have the additional benefit of relieving dysmenorrhoea (see review on dysmenorrhoea).
Compared with NSAIDs Tranexamic acid may be more effective at reducing blood loss (very low-quality evidence).
Compared with etamsylate Tranexamic acid may be more effective at reducing blood loss (very low-quality evidence).
Compared with oral progestogens (luteal phase) Tranexamic acid may be more effective at reducing blood loss (low-
quality evidence).
Compared with endometrial resection Tranexamic acid may be less effective at reducing menstrual blood loss at 4
months and 2 years (low-quality evidence).
Adverse effects
Tranexamic acid may increase the proportion of women with adverse effects over 4 months compared with endome-
trial resection. Adverse effects of tranexamic acid include leg cramps and nausea, which occur in about a third of
women using this drug.
Note
We found no clinically important information about the effects of tranexamic acid compared with danazol, combined
oral contraceptives, or gonadorelin analogues.
Harms: Nausea and leg cramps occur in a third of women taking tranexamic acid. Isolated case reports
have suggested a risk of thromboembolism associated with tranexamic acid, but a large population-
based study conducted over 19 years found no evidence that this was higher than expected in the
[20]
general population.
Comment: The RCT comparing tranexamic acid, etamsylate, and mefenamic acid reported that 27% of
women withdrew from the study before its end, and made no adjustment for the multiple treatment
[17]
comparisons involved.
© BMJ Publishing Group Ltd 2008. All rights reserved. ........................................................... 5
Women's health
Menorrhagia
Clinical guide:
Unlike NSAIDs, tranexamic acid has no effect on dysmenorrhoea.
OPTION ETAMSYLATE. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Compared with tranexamic acid Etamsylate may be less effective at reducing blood loss (very low-quality evidence).
Note
We found no clinically important results about the effects of etamsylate compared with danazol, combined oral con-
traceptives, oral progestogens, intrauterine progestogens, or gonadorelin analogues.
Harms: The review found no significant difference between different drug regimens in the rate of adverse
effects (nausea, headaches, and dizziness), and these adverse effects seldom caused women to
[16]
withdraw from studies.
Comment: The RCT comparing tranexamic acid, etamsylate, and mefenamic acid reported that 27% of
women withdrew from the study before its completion, and made no adjustment for the multiple
[17]
treatment comparisons involved.
OPTION DANAZOL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Compared with NSAIDs Danazol is more effective at reducing mean blood loss (moderate-quality evidence).
Compared with the combined oral contraceptive pill We don't know how effective danazol is at reducing mean blood
loss compared with the combined oral contraceptive pill (moderate-quality evidence).
Compared with oral progestogens (luteal phase) Danazol is more effective than oral progestogens in the luteal phase
at reducing blood loss (moderate-quality evidence).
Compared with progestogen-releasing IUD We don't know how effective danazol is compared with progestogen-re-
leasing IUDs at reducing mean blood loss (very low-quality evidence).
Compared with endometrial ablation Danazol may be less effective at reducing blood loss at 4 months and at 2 years
(low-quality evidence).
Adverse effects
Danazol has more adverse effects compared with NSAIDs, oral progestogens, or endometrial ablation.
Note
We found no clinically important results about the effects of danazol compared with tranexamic acid or gonadorelin
analogues.
© BMJ Publishing Group Ltd 2008. All rights reserved. ........................................................... 6
Women's health
Menorrhagia
For GRADE evaluation of interventions for menorrhagia, see table, p 22 .
Different regimens:
We found one systematic review (search date 2007), which included two small RCTs comparing
different danazol regimens: standard dose danazol (200 mg/day), lower dose danazol (100 mg/day),
[13]
and a reducing-dose regimen. It found no significant difference in blood loss, frequency of ad-
verse events, or duration of menstruation when a dose of 200 mg daily was compared with a re-
ducing-dose regimen (WMD for mean menstrual blood loss +33.5 mL, 95% CI –32.4 mL to +99.4 mL;
OR for proportion of women reporting adverse events 1.13, 95% CI 0.14 to 9.07; WMD for duration
of menstruation +1.3 days, 95% CI –0.76 days to +3.36 days).
Compared with danazol We don't know how effective combined oral contraceptives are at reducing mean blood loss
compared with danazol (moderate-quality evidence).
Compared with endometrial resection Oral contraceptives may be less effective at reducing menstrual blood loss at
4 months and at 2 years (low-quality evidence).
Note
We found no clinically important results about the effects of combined oral contraceptives compared with other drugs.
Harms: Minor adverse effects are common, and include nausea, headache, breast tenderness, changes
in body weight, hypertension, changes in libido. Contraceptives can also cause depression.
Comment: One non-RCT (164 women) found that a 50 mg oral contraceptive pill led to a 53% reduction in
[22]
menstrual blood loss from baseline. Two longitudinal case control studies found that women
taking the contraceptive pill were less likely than those not taking the pill to experience heavy
[23] [24]
menstrual bleeding or anaemia.
Compared with danazol Oral progestogens given in the luteal phase are less effective at reducing blood loss (mod-
erate-quality evidence).
Compared with tranexamic acid Oral progestogens given in the luteal phase may be less effective at reducing blood
loss (low-quality evidence).
Compared with endometrial resection Oral progestogens given in the luteal phase may be less effective at reducing
blood loss at 4 months and at 2 years (low-quality evidence).
Note
We found no direct information about whether oral progestogens are better than no active treatment.
© BMJ Publishing Group Ltd 2008. All rights reserved. ........................................................... 8
Women's health
Menorrhagia
For GRADE evaluation of interventions for menorrhagia, see table, p 22 .
Harms: The review found that adverse effects (including headache, breast tenderness, premenstrual
symptoms, and gastrointestinal disturbances) were reported in between a third and a half of the
[18]
women taking oral progestogens.
Comment: None.
Adverse effects
Half of the women taking oral progestogens may feel unwell.
Note
We found no direct information about whether oral progestogens are better than no active treatment.
Comment: None.
Compared with endometrial ablation Intrauterine progestogens may be less effective at reducing pictorial blood loss
assessment (PBAC) scores (low-quality evidence).
Quality of life
Compared with hysterectomy progestogen-releasing IUDs and hysterectomy are equally effective at improving
quality of live and patient satisfaction at 1 year (moderate-quality evidence).
Adverse effects
The risk of serious adverse effects is lower with intrauterine progestogens compared with hysterectomy.
Note
We found no direct information about whether intrauterine progestogens are better than no active treatment.
Benefits: We found no systematic review or RCTs comparing intrauterine progestogens versus placebo.
[18]
We found three systematic reviews (search date not reported, 1 RCT; search date 2005, 10
[25] [26]
RCTs; search date 2005, 8 RCTs; with 6 RCTs common to all) and two subsequent RCTs
[27] [28]
comparing intrauterine progestogens versus other drugs or versus surgical treatment.
Harms: There are concerns that progestogen-releasing IUDs increase rates of ectopic pregnancy, although
[25]
the RCT identified by the first systematic review did not report this adverse effect. RCTs looking
at the contraceptive effect of progestogen-releasing IUD in younger women found that, during the
first few months of use, the total number of bleeding days (including menstrual bleeding, intermen-
[29]
strual bleeding, and spotting) increased in most women. However, most women bled lightly for
[30]
only 1 day a month, and about 15% were amenorrhoeic after 12 months.
Comment: Long-term follow-up in women with menorrhagia is required to assess continuation rates, satisfaction,
and whether surgical treatment is avoided or just postponed. The trials that considered long-term
bleeding patterns were mainly in women under 40 years of age. It is not yet known whether these
results can be extrapolated to older women with menorrhagia.
We found no direct information about the effects of gonadorelin analogues in women with menorrhagia.
We found no direct information about the effects of dilatation and curettage in women with menorrhagia.
Harms: Observational evidence suggests that dilatation and curettage may cause adverse effects including
[34]
uterine perforation and cervical laceration, as well as the usual risks of general anaesthesia.
OPTION HYSTERECTOMY. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Subtotal compared with total hysterectomy Subtotal hysterectomy is more likely to result in ongoing cyclical bleeding
in women with benign gynaecological disease including menorrhagia (moderate-quality evidence).
Quality of life
Postoperative recovery
Abdominal compared with laparoscopic or vaginal hysterectomy Postoperative recovery is faster with vaginal or la-
paroscopic hysterectomy in women with benign gynaecological disease including menorrhagia (moderate-quality
evidence).
Adverse effects
Compared with endometrial destruction Hysterectomy is associated with a higher risk of intraoperative and postop-
erative complications (moderate-quality evidence).
Subtotal compared with total hysterectomy Complication rates are similar for subtotal compared with total hysterec-
tomy (moderate-quality evidence).
Abdominal compared with vaginal hysterectomy Postoperative mortality may be greater with abdominal hsyterectomy
(very low-quality evidence).
Abdominal compared with vaginal and laparoscopic hysterectomy Complications of surgery are greater with abdom-
inal or laparoscopic hysterectomy (moderate-quality evidence).
Compared with progestogen-releasing IUD Serious adverse effects are more likely after hysterectomy (moderate-
quality evidence).
Harms: One large population-based analysis stratified by age found that mortality after hysterectomy for
[40]
non-malignant conditions is about 1/2000 in women aged under 50 years.
Comment: None.
Compared with oral drugs Endometrial destruction may be more effective than tranexamic acid, danazol, oral pro-
gestogens, or combined oral contraceptives at reducing blood loss (low-quality evidence).
Compared with hysterectomy Endometrial destruction is less effective at reducing menstrual blood loss, and increases
the number of women requiring further operations (high-quality evidence).
Adverse effects
Different techniques of endometrial destruction Different techniques are associated with different adverse effects
(moderate-quality evidence).
Compared with hysterectomy Endometrial destruction is associated with a lower risk of intraoperative and postoper-
ative complications (moderate-quality evidence). Recognised complications of endometrial destruction techniques
include infection, haemorrhage, and uterine perforation.
Postoperative amenorrhoea
Compared with placebo Preoperative gonadorelin analogues (GnRHa) are more effective than placebo or no preop-
erative treatment at reducing postoperative moderate or heavy menstrual blood loss at 6–12 months after surgery,
and at increasing amenorrhoea at 24 months after surgery (moderate-quality evidence).
Compared with danazol GnRHa and danazol are equally effective at producing postoperative amenorrhoea at 12
months (high-quality evidence).
Compared with oral progestogens We don't know how effective GnRHa are at increasing postoperative amenorrhoea
compared with oral progestogens (low-quality evidence).
OPTION DANAZOL. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Postoperative amenorrhoea
Compared with gonadorelin analogues Gonadorelin analogues and danazol are equally effective at producing post-
operative amenorrhoea at 12 months (high-quality evidence).
Compared with oral progestogens We don't know how effective danazol is at producing postoperative amenorrhoea
compared with oral progestogens (low-quality evidence).
Comment: None.
Postoperative amenorrhoea
Compared with no preoperative treatment Oral progestogens are no more effective at producing postoperative
amenorrhoea (moderate-quality evidence).
Compared with danazol We don't know how effective oral progestogens are at producing postoperative amenorrhoea
compared with danazol (low-quality evidence).
Comment: None.
SUBSTANTIVE CHANGES
Endometrial destruction Two RCTs added comparing either first- with second-generation techniques, or first-gen-
[43] [44]
eration techniques with each other. The first RCT compared thermal balloon endometrial ablation with tran-
scervical endometrial resection, and found both treatments reduced menstrual blood loss compared with baseline.
[43]
The second RCT (10-year follow-up of a trial included in the systematic review) compared rollerball ablation and
transcervical endometrial resection. The follow-up found no difference between groups for rates of hysterectomy.
[44]
Categorisation unchanged (Likely to be beneficial).
Intrauterine progestogens One RCT added comparing progestogen-releasing IUD versus thermal balloon ablation
[28]
at 12-month follow-up. The RCT found that the progestogen-releasing IUD significantly reduced PBAC scores
at 12 months compared with thermal balloon ablation. However, the progestogen-releasing IUD was associated with
higher hysterectomy rates at 24 months compared with the thermal balloon. Owing to the small numbers included
in the trial, the categorisation remains as Unknown effectiveness.
[19]
Tranexamic acid One RCT added comparing tranexamic acid with medroxyproesterone acetate. There was
no direct comparison of menstrual blood loss between groups, but the reduction from baseline was reported for both
groups. The RCT found that both treatments reduced menstrual blood loss from baseline at 3 months. Categorisation
unchanged (Beneficial).
REFERENCES
1. Hallberg L, Hogdahl A, Nilsson L, et al. Menstrual blood loss– a population study: 8. Coulter A, McPherson K, Vessey M. Do British women undergo too many or too
variation at different ages and attempts to define normality. Acta Obstet Gynecol few hysterectomies? Soc Sci Med 1988;27:987–994.[PubMed]
Scand 1966;45:320–351.[PubMed] 9. Pokras R, Hufnagel VG. Hysterectomies in the United States. Vital Health Stat
2. Vessey MP, Villard-Mackintosh L, McPherson K, et al. The epidemiology of Series 13 1987;92:1–32.
hysterectomy: findings in a large cohort study. Br J Obstet Gynaecol 10. Coulter A, Kelland J, Long A. The management of menorrhagia. Effective Health
1992;99:402–407.[PubMed] Care Bull 1995;9:1–14.
3. Working Party of the National Health Committee New Zealand. Guidelines for 11. Clarke A, Black N, Rowe P, et al. Indications for and outcome of total abdominal
the management of heavy menstrual bleeding. Wellington: Ministry of Health, hysterectomy for benign disease: a prospective cohort study. Br J Obstet Gynaecol
1998 (available from The Ministry of Health, 133 Molesworth Street, PO Box 1995;102:611–620.[PubMed]
5013, Wellington, New Zealand). Search date 1996; primary sources Medline,
12. Lethaby A, Augood C, Duckitt K. Nonsteroidal anti-inflammatory drugs for heavy
Embase, Current Contents, Biological Abstracts, Social Sciences Index, Psychlit,
menstrual bleeding In: The Cochrane Library: Issue 3, 2007. Chichester, UK:
and Cinahl.
John Wiley & Sons, Ltd. Search date 2001; primary sources Cochrane Menstrual
4. Smith SK, Abel MH, Kelly RW, et al. A role for prostacyclin (PGI2) in excessive Disorders and Subfertility Group trials register, Medline, Embase, Psychlit, Current
menstrual bleeding. Lancet 1981;1:522–524.[PubMed] Contents, Biological Abstracts, Social Sciences Index, Cinahl, reference lists,
5. Rybo G, Leman J, Tibblin R. Epidemiology of menstrual blood loss. In: Baird DT, and drug companies.
Michie EA, eds. Mechanisms of menstrual bleeding. New York: Raven Press, 13. Beaumont H, Augood C, Duckitt K, et al. Danazol for heavy menstrual bleeding.
1985:181–193. In: The Cochrane Library: Issue 3, 2007. Chichester, UK: John Wiley & Sons,
6. Alexander DA, Naji AA, Pinion SB, et al. Randomised trial comparing hysterectomy Ltd. Search date 2001; primary sources Medline, Embase, Current Contents,
with endometrial ablation for dysfunctional uterine bleeding: psychiatric and Cinahl, National Research Register, Menstrual Disorders and Subfertility Group
psychosocial aspects. BMJ 1996;312:280–284.[PubMed] Specialised Register, reference lists, and contact with authors.
7. Coulter A, Peto V, Jenkinson C. Quality of life and patient satisfaction following 14. Lethaby A, Farquhar C, Cooke I. Antifibrinolytics for heavy menstrual bleeding.
treatment for menorrhagia. Fam Pract 1994;11:394–401.[PubMed] In: The Cochrane Library: Issue 3, 2007. Chichester, UK: John Wiley & Sons,
Ltd. Search date 1997; primary sources Cochrane Menstrual Disorders and
Kirsten Duckitt
Department of Obstetrics and Gynaecology
Milton Keynes Hospital NHS Foundation Trust
Milton Keynes
UK
Sally Collins
Specialist Registrar
John Radcliffe Hospital
Oxford
UK
Competing interests: KD is the co-author of two systmatic reviews referenced in this review. She has also been reimbursed by Berlex, Canada, for speaking on menorrhagia.
SC declares that she has no competing interests.
The information contained in this publication is intended for medical professionals. Categories presented in Clinical Evidence indicate a
judgement about the strength of the evidence available to our contributors prior to publication and the relevant importance of benefit and
harms. We rely on our contributors to confirm the accuracy of the information presented and to adhere to describe accepted practices.
Readers should be aware that professionals in the field may have different opinions. Because of this and regular advances in medical research
we strongly recommend that readers' independently verify specified treatments and drugs including manufacturers' guidance. Also, the
categories do not indicate whether a particular treatment is generally appropriate or whether it is suitable for a particular individual. Ultimately
it is the readers' responsibility to make their own professional judgements, so to appropriately advise and treat their patients. To the fullest
extent permitted by law, BMJ Publishing Group Limited and its editors are not responsible for any losses, injury or damage caused to any
person or property (including under contract, by negligence, products liability or otherwise) whether they be direct or indirect, special, inci-
dental or consequential, resulting from the application of the information in this publication.
Type Con-
Number of studies of evi- sisten- Direct- Effect
(participants) Outcome Comparison dence Quality cy ness size GRADE Comment
What are the effects of medical treatments for menorrhagia?
[3]
12 (313) Mean menstrual blood loss NSAIDs v placebo 4 0 0 –1 0 Moderate Directness point deducted for differences in
regimens between studies
[12]
2 (61) Mean menstrual blood loss NSAIDs v each other 4 –1 0 –1 0 Low Quality point deducted for sparse data. Direct-
ness point deducted for small number of compar-
isons
[14] [3] [17]
4 (164) Mean menstrual blood loss NSAIDs v tranexamic acid 4 –3 0 0 0 Very low Quality points deducted for sparse data, poor
follow-up, and other methodological flaws
[17]
1 (81) Mean menstrual blood loss NSAIDs v etamsylate 4 –3 0 0 0 Very low Quality points deducted for sparse data, poor
follow-up, and other methodological flaws
[12] [13]
3 (79) Mean menstrual blood loss NSAIDs v danazol 4 –1 0 0 0 Moderate Quality point deducted for sparse data
[12] [13] [21]
1 (38) Mean menstrual blood loss NSAIDs v combined oral contracep- 4 –1 0 0 0 Moderate Quality point deducted for sparse data
tives
[12]
2 (48) Mean menstrual blood loss NSAIDs v oral progestogens (luteal 4 –1 0 0 0 Moderate Quality point deducted for sparse data
phase)
7 (At least 153 peo- Mean menstrual blood loss Tranexamic acid v placebo 4 –2 0 0 0 Low Quality points deducted for sparse data and in-
[3] [14]
ple) complete presentation of results
[17]
1 (81) Mean menstrual blood loss Tranexamic acid v etamsylate 4 –3 0 0 0 Very low Quality points deducted for sparse data, poor
follow-up, and other methodological flaws
[15] [19]
2 (146) Mean menstrual blood loss Tranexamic acid v oral progestogens 4 –2 0 0 0 Low Quality points deducted for sparse data and
(luteal phase) methodological flaws
[26]
1 (187) Mean menstrual blood loss Tranexamic acid v endometrial resec- 4 –1 0 –1 0 Low Quality point deducted for sparse data. Direct-
tion ness point deducted for range of drugs in com-
parison
[17]
1 (81) Mean menstrual blood loss Etamsylate v NSAIDs 4 –3 0 0 0 Very low Quality points deducted for sparse data, poor
follow-up, and other methodological flaws
[13] [3]
4 (193) Mean menstrual blood loss Danazol v placebo 4 –2 0 –1 0 Very low Quality points deducted for sparse data and in-
complete presentation of results. Directness
point deducted for indirect comparisons
[13] [12] [21]
1 (38) Mean menstrual blood loss Danazol v combined oral contracep- 4 –1 0 0 0 Moderate Quality point deducted for sparse data
tive pill
[18]
2 (51) Mean menstrual blood loss Danazol v oral progestogens (luteal 4 –1 0 0 0 Moderate Quality point deducted for sparse data
phase)
[26]
1 (187) Mean menstrual blood loss Danazol v endometrial ablation 4 –1 0 –1 0 Low Quality point deducted for sparse data. Direct-
ness point deducted for range of drugs in com-
parison